-
Entrada Reports Positive Topline Results from Phase 1/2 ELEVATE-44-201 Study in Duchenne
Entrada Therapeutics has announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple
-
Protected: CureDuchenne Expands Global Duchenne Care Efforts Through First Latin American Symposium in Chile
This content is password protected. To view it please enter your password below: Password: The
-
Momentum Continues: Duchenne Newborn Screening Advances Across the US
Duchenne was added to the Recommended Uniform Screening Panel (RUSP) (RUSP) on December 16, 2025,
-
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne
Solid Biosciences Inc. has shared that the first participant has been dosed in IMPACT DUCHENNE,
-
First Participant Dosed in Phase 3 Trial for SGT-003 in Duchenne
Solid Biosciences has announced the first participant has been dosed in the Phase 3 IMPACT
-
One way to process loss is by advocating for lasting change
The death of my dear friend Timothy Chan last month still affects me deeply. A
-
STAT: A decade ago, these drugs tore apart the FDA. Today might be some patients’ best hope.
By Jason Mast Stat ArticleDownload The post STAT: A decade ago, these drugs tore apart
-
European regulators back new DMD gene therapy with key status
Regulators in the European Union have granted orphan drug designation to SGT-003, a gene therapy
-
MDA Ambassador Guest Blog: ALS is Not the End of My Story
Monica Torres is a 42-year-old mom of 6. Monica was born and raised in Puerto
-
Global Nonprofit CureDuchenne to Host FUTURES National Conference for the Duchenne and Becker Muscular Dystrophy Community on May 21-24 in Orlando, FL
Four-Day Conference Will Feature Leading Experts, Inspirational Speakers,and the Latest Care and Treatment Insights Newport
